Ernexa Therapeutics Q3 2026 Results: Net Loss of $2.94M, Loss Widens
Ernexa Therapeutics reported a net loss of $12.5 million for the nine months ended September 30, 2026, which included a $2.0 million goodwill impairment charge. The company strengthened its cash position to $5.6 million through public offerings and ATM stock issuances, while research and development expenses nearly doubled compared to the prior year.
- Key figure
- Net loss $2.94M